About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Breast Cancer Clinical Trials in Portland | 444 Studies

Clinical Trials Breast CancerPortland

Breast Cancer Clinical Trials in Portland

Find 444 clinical trials for breast cancer near Portland, Oregon. Connect with research centers in your area.

All Breast Cancer trials nationwide All trials in Portland

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 401-420 of 444 trials

RecruitingBAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid LeukemiaThis study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination…NCT05768932·New Haven, Connecticut and 16 others CompletedEfficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer RecurrencePurpose of this trial: 1. To assess the efficacy and safety of NeuVax™ administered with adjuvant Leukine® (sargramostim, GM-CSF).NCT01479244·Bessemer, Alabama and 196 others

Breast Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedExemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of TamoxifenRATIONALE: Estrogen can stimulate the growth of breast cancer cells.NCT00016432·Huntsville, Alabama and 161 others

CompletedIncidence of Cancer in Women at Increased Genetic Risk of Ovarian CancerThis clinical trial is studying the incidence of cancer in women at increased genetic risk of ovarian cancer.NCT01139957·Birmingham, Alabama and 140 others

RecruitingPembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabThis phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients…NCT05812807·Birmingham, Alabama and 845 others

CompletedRandomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or MetastaticThe purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared…NCT00696072·Sedona, Arizona and 26 others

UnknownPrevention of Capsular Contracture Using Trental and Vitamin EThe main purpose of this research study is to determine if the use of Trental and Vitamin E will decrease the incidence and severity of contractures (shrinking and or hardening of…NCT01082003·Portland, Oregon

Active not recruitingA Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care…NCT05104866·Duarte, California and 166 others

RecruitingStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe…NCT05633654·Birmingham, Alabama and 377 others

WithdrawnTucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.This is an open label study of tucatinib in combination with either vinorelbine or gemcitabine and trastuzumab in patients with metastatic HER2+ breast cancer.NCT04896320·Clackamas, Oregon and 3 others

RecruitingShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabThis phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive…NCT06876714·Phoenix, Arizona and 701 others

Active not recruitingTamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast CancerThis randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treating patients with breast cancer that has spread to nearby…NCT02311933·Mobile, Alabama and 558 others

Active not recruitingA Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseThe study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the…NCT04711252·Mobile, Alabama and 262 others

Active not recruitingAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer…NCT05952557·Dothan, Alabama and 660 others

CompletedUse of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related SymptomsThis clinical trial evaluates the use of virtual reality (VR) goggles during chemotherapy infusion to reduce anxiety-related symptoms in patients with head and neck, thoracic…NCT05793957·Portland, Oregon

CompletedRandomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast CancerTo compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already…NCT00038467·Birmingham, Alabama and 376 others

RecruitingI-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerThe purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast…NCT01042379·Birmingham, Alabama and 41 others

CompletedA Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib.NCT00428220·Atlanta, Georgia and 112 others

Active not recruitingTesting MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerThis randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer.NCT02954874·Birmingham, Alabama and 918 others

CompletedS9630, Medroxyprogesterone in Treating Women With Breast CancerRATIONALE: It is not yet known whether medroxyprogesterone is effective in preventing endometrial disorder in patients with breast cancer who are taking tamoxifen.NCT00002920·Mobile, Alabama and 121 others

PreviousPage 21 of 23Next

Other Conditions in Portland

Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma